Bayer and Dewpoint Therapeutics, a biotechnology company with sites in Boston and Dresden, Germany, today announced an option, research and license agreement worth up to USD 100 million. The partnership will leverage Dewpoint’s proprietary platform for biomolecular condensates and Bayer’s small molecule compound library to develop new treatments for cardiovascular and gynecological diseases.
Today, around 80 percent of the human proteome is still considered to be beyond the reach of small molecules, which make up more than 80 percent of all marketed therapeutic drugs. The emerging paradigm of biomolecular condensates is expanding the traditional drug target space for small molecules by unveiling new targets and new approaches to previously intractable targets.
